Search

Your search keyword '"Zechmann, C. A."' showing total 4 results
Start Over Author "Zechmann, C. A." Search Limiters Full Text
4 results on '"Zechmann, C. A."'

1. Prevalence and significance of neck node metastases from oesophageal and stomach cancer at presentation

Author

Griffith, J F, Ahuja, A T, Chan, A C W, Ng, E, Leung, S F, Ng, C N, Leung, D K, Chow, L T C, Chung, S C S, Giesel, F L, Bongers, A, Zechmann, C, von Tengg-Kobligk, H, Weber, M A, Delorme, S, Ley, S, Kauczor, H U, Essig, M, Thoeny, Harriet C, De Keyzer, Frederik, Vandecaveye, Vincent, Chen, Feng, Verbeken, Eric K, Boesch, Chris, Ni, Yicheng, Landuyt, Willy, Marchal, Guy, Hermans, Robert, Vandecaveye, V, De Keyzer, F, Landuyt, W, Thoeny, H C, Sun, X, Chen, F, Marchal, G, Thys, M, Ni, Y, Hermans, R, Biscaldi, E, Comandini, D, Sciallero, S, Sobrero, A, Rollandi, G A, Kayani, I, Syed, R, Pakzad, F, Nagabushan, N, Groves, A M, Croasdale, I, Bomanji, J, Ell, P J, Petralia, G, Funicelli, L, Ferretti, S, Sonzogni, A, Bellomi, M, Bergman, A, Krause, J, Mahteme, H, Graf, W, Masselli, G, Manfredi, R, Brizi, M G, Nuzzo, G, Vecchioli, A, and Marano, P more...

Subjects
Symposium, Article
Published
2005

2. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy

Author

Giesel, F.L., Flechsig P., Kuder T., Schwartz L., Wulfert S., Zechmann C., Bruchertseifer F., Haberkorn U., and Kratochwil C.

Subjects
Original contributions
Abstract

Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage after radiation therapy appears slowly. In some solid tumors a decline in tumor perfusion was found predictive of final treatment response but the gold standard multiphase computed tomography (CT) has a high radiation burden. Therefore we evaluated the ability of contrast-enhanced ultrasound (CEUS) to evaluate tumor perfusion as a response criteria. 14 patients with hepatic neuroendocrine tumor (NET) metastases were enrolled in the retrospective study. Eleven patients were treated with beta-emitting ¹⁷⁷Lu/⁹⁰Y-DOTATOC, either intravenous (i.v.) (n = 5) or intra-arterial (i.a.) (n = 6) and three patients received alpha-emitting ²¹³Bi-DOTATOC (i.a.). CEUS and contrast-enhanced CT (CE-CT) were performed before and 3 months after treatment. CE-CT and CEUS presented comparable results in the baseline study and in the assessment of perfusion changes due to the different treatment regimes. A therapy related decrease in tumor perfusion is an early predictor of longterm morphologic response. Conclusion: CEUS is available and radiation free technique which showed comparable results for perfusion and diameter of liver metastases compared to CE-CT. Intensity reduction in an arterial phase CEUS can be seen as a positive sign indicating long term tumor response to treatment. Therefore CEUS may be considered as an imaging modality for monitoring early treatment after focal alpha and beta targeted therapy. Key Words: contrast-enhanced ultrasound, radionuclide therapy, treatment response, DOTATOC PET/CT. more...

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results

3. Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer

Author

Gilbert, F. J., Van Den Bosch, H. C. M., Petrillo, A., Siegmann, K., Heverhagen, J. T., Panizza, P., Gehl, H. -B., Pediconi, F., Diekmann, F., Peng, W. -J., Ma, L., Sardanelli, F., Belli, Paolo, Corcione, S., Zechmann, C. M., Faivre-Pierret, M., Martincich, L., Belli P. (ORCID:0000-0001-7979-2466), Gilbert, F. J., Van Den Bosch, H. C. M., Petrillo, A., Siegmann, K., Heverhagen, J. T., Panizza, P., Gehl, H. -B., Pediconi, F., Diekmann, F., Peng, W. -J., Ma, L., Sardanelli, F., Belli, Paolo, Corcione, S., Zechmann, C. M., Faivre-Pierret, M., Martincich, L., and Belli P. (ORCID:0000-0001-7979-2466) more...

Published
2014

4. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study

Author

Scheenen, T.W.J., Futterer, J.J., Weiland, E., Hecke, P. van, Lemort, M., Zechmann, C., Schlemmer, H.P., Broome, D., Villeirs, G., Lu, J., Barentsz, J.O., Roell, S., Heerschap, A., Scheenen, T.W.J., Futterer, J.J., Weiland, E., Hecke, P. van, Lemort, M., Zechmann, C., Schlemmer, H.P., Broome, D., Villeirs, G., Lu, J., Barentsz, J.O., Roell, S., and Heerschap, A. more...

Abstract

Item does not contain fulltext, OBJECTIVES: A prospective multicenter validation of the ability of 1H magnetic resonance spectroscopic imaging (MRSI) to distinguish cancer from noncancer tissues throughout the prostate with histopathology of the resected organ as the standard of reference. MATERIALS AND METHODS: Institutional review board approval was obtained for all centers and all participating patients and volunteers provided written informed consent. Ninety-nine patients and 10 age-matched volunteers from 8 participating centers underwent magnetic resonance imaging and 3-dimensional MRSI with an endorectal coil at 1.5 T. Selected MRSI voxels were assigned to the peripheral zone (PZ), the central gland (CG), the periurethral area, and cancer tissue. Signal ratios of choline + creatine to citrate (CC/C) in spectra of these voxels were automatically calculated. Receiver operating characteristic curves were constructed to assess the accuracy by which this ratio can discriminate cancer from noncancer tissue. RESULTS: A total of 70% of voxels in noncancer tissue and 90% of voxels in cancer tissue passed the quality check of the automatically fitted spectra. The median CC/C was significantly different between any noncancer and cancer tissue (P < 0.0001), but not between the different contributing centers. CC/C increased with cancer focus size (P =0.0008) and certainty of voxel mapping to histopathologic cancer site (P 0.0001). The area under the receiver operating characteristic curve for discriminating voxels of cancer tissue from noncancer tissue was 0.88 (confidence interval: 0.84-0.92) in the PZ and 0.76 (confidence interval: 0.71- 0.81) in the CG. more...

Published
2011